Share This Page
Suppliers and packagers for mupirocin
✉ Email this page to a colleague
mupirocin
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Alembic | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213053 | ANDA | Alembic Pharmaceuticals Limited | 46708-624-15 | 1 TUBE in 1 CARTON (46708-624-15) / 15 g in 1 TUBE | 2025-03-18 |
| Alembic | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213053 | ANDA | Alembic Pharmaceuticals Limited | 46708-624-30 | 1 TUBE in 1 CARTON (46708-624-30) / 30 g in 1 TUBE | 2025-03-18 |
| Alembic | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213053 | ANDA | Alembic Pharmaceuticals Inc. | 62332-624-15 | 1 TUBE in 1 CARTON (62332-624-15) / 15 g in 1 TUBE | 2021-12-01 |
| Alembic | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213053 | ANDA | Alembic Pharmaceuticals Inc. | 62332-624-30 | 1 TUBE in 1 CARTON (62332-624-30) / 30 g in 1 TUBE | 2021-12-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Mupirocin
Introduction
Mupirocin is an antibiotic primarily used to treat skin infections and nasal carriage of Staphylococcus aureus, including methicillin-resistant strains (MRSA). Recognized for its efficacy against Gram-positive bacteria, mupirocin plays a vital role in hospital and outpatient settings. As demand for effective antimicrobial agents grows amid rising antibiotic resistance, understanding the landscape of mupirocin suppliers becomes crucial for pharmaceutical companies, healthcare providers, and policymakers. This article comprehensively analyzes key suppliers of mupirocin, examining manufacturing capacities, the global supply chain, and strategic considerations for stakeholders.
Market Overview and Demand Dynamics
The global mupirocin market has expanded alongside heightened infection control measures, especially during the COVID-19 pandemic, which emphasized the need for effective nasal decolonization strategies to prevent secondary bacterial infections. Predominantly, mupirocin is formulated as topical ointments, creams, and nasal sprays, with major markets in North America, Europe, and Asia-Pacific. The surge in antimicrobial resistance (AMR) has resulted in increased procurement from both public and private sectors, heightening the importance of reliable suppliers.
Major Suppliers and Manufacturing Players
1. GlaxoSmithKline (GSK)
As a pioneer in mupirocin production, GSK holds an extensive patent portfolio and manufacturing facilities for mupirocin-based formulations, including Bactroban. The company's global distribution network ensures a steady supply across multiple markets. GSK’s deep R&D pipeline and manufacturing scale allow it to meet rising global demand, especially for nasal mupirocin, which is pivotal in MRSA decolonization protocols [1].
2. Sandoz (Novartis Group)
Sandoz is a leading generic pharmaceutical manufacturer with significant production capacity for mupirocin ointments. It supplies generic equivalents of Bactroban in numerous countries, providing cost-effective options for healthcare providers. Sandoz's focus on high-volume manufacturing and compliance with international regulatory standards enhances its global footprint.
3. Teva Pharmaceutical Industries Ltd.
Teva is among the world's largest producers of generic medicines, including mupirocin. The company has robust manufacturing facilities primarily in Israel and Europe, coupled with an aggressive distribution network. Teva's focus on quality control and capacity expansion has made it a key player in meeting the increasing global demand.
4. Mylan (Now Viatris)
Viatris, formed from the merger of Mylan and Pfizer's generics business, supplies mupirocin in multiple regions. It offers formulations comparable to branded products and has invested in manufacturing scalability and regulatory compliance, ensuring broad access across developed and emerging markets.
5. Other Notable Manufacturers
Additional suppliers include:
- Alconbury Weston in the UK, historically involved in mupirocin production.
- Dong-A ST in South Korea, an emerging regional supplier.
- Haerim Pharm Co. Ltd. in South Korea, engaged in manufacturing for local and export markets.
The competitive landscape is characterized by a mix of established pharmaceutical companies and regional players, often engaging in licensing agreements and joint ventures to expand production capacities.
Manufacturing Challenges and Supply Chain Considerations
Raw Material Sourcing
Mupirocin synthesis hinges on specialized raw materials and precursor chemicals, such as 2,4-dimethylpent-4-enoic acid. Fluctuations in the availability of these intermediates, affected by geopolitical tensions or supply chain disruptions, can impact production capacity.
Quality and Regulatory Compliance
Suppliers face stringent regulatory standards, including WHO GMP accreditation, EMA, and FDA approval. Non-compliance risks delays and supply shortages, emphasizing the importance of quality assurance systems.
Manufacturing Scale-Up and Capacity
The global push for antimicrobial availability necessitates continuous capacity expansion. Suppliers invest in biosynthesis and chemical synthesis processes, optimizing yields and reducing manufacturing costs to accommodate increasing demand.
Strategic Considerations for Stakeholders
Diversification of Supply Sources
To mitigate risks stemming from dependency on a limited number of suppliers, pharmaceutical companies should diversify their sourcing strategies. Engaging with multiple approved manufacturers ensures continuity and competitiveness.
Leveraging Regional Suppliers
Regional manufacturers can offer strategic advantages in cost, logistical efficiency, and regulatory compliance. For instance, South Korean firms like Dong-A ST are gaining prominence, especially within Asian markets.
Investing in Supply Chain Resilience
Building relationships with suppliers that possess scalable manufacturing capacities, robust quality controls, and transparent supply chain logistics is imperative. Strategic stockpiling and contractual agreements can buffer against unforeseen disruptions.
Emerging Trends and Future Outlook
- Biotechnological innovations aim to develop new microbial synthesis methods to enhance mupirocin production efficiency.
- Regulatory shifts focusing on antimicrobial stewardship could impact patent statuses, market access, and manufacturing practices.
- Market consolidation as larger firms acquire smaller regional players to bolster market share and diversify supply bases.
- Environmental considerations are increasingly influencing manufacturing processes, prompting suppliers to adopt greener practices.
Conclusion
The current landscape of mupirocin supply is characterized by a combination of established global giants like GSK, Sandoz (Novartis), Teva, and Viatris, alongside regional players expanding into emerging markets. For continued reliability, stakeholders must prioritize diversified sourcing, investment in manufacturing capacity, and compliance with regulatory standards. As the battle against antimicrobial resistance intensifies, the strategic positioning of mupirocin suppliers will be instrumental in ensuring supply stability, innovation, and global health security.
Key Takeaways
- GSK, Sandoz, Teva, and Viatris dominate the global mupirocin supply chain, providing both branded and generic formulations.
- Raw material sourcing and manufacturing capacity are critical factors influencing supply stability amid rising demand.
- Diversifying suppliers and regional manufacturing partnerships can mitigate risks from geopolitical or supply chain disruptions.
- Regulatory compliance and quality assurance are non-negotiable for maintaining market access and production continuity.
- Innovation in synthesis and environmentally sustainable manufacturing practices are future trends shaping the mupirocin supply landscape.
FAQs
1. Who are the leading manufacturers of mupirocin worldwide?
Leading manufacturers include GlaxoSmithKline, Sandoz (a Novartis division), Teva Pharmaceutical Industries, and Viatris, each supplying branded and generic formulations globally.
2. What are the main challenges faced by mupirocin suppliers?
Challenges include sourcing specialized raw materials, adhering to stringent regulatory standards, scaling manufacturing capacities, and managing supply chain disruptions.
3. How does regional supply affect global mupirocin availability?
Regional suppliers can enhance supply resilience by providing localized production, reducing logistical delays, and catering to specific regional regulatory requirements.
4. Are there new entrants or innovations in mupirocin manufacturing?
Emerging biotechnological methods aim to improve synthesis efficiency, reduce costs, and develop environmentally sustainable manufacturing processes, potentially transforming the supply chain.
5. How can healthcare providers ensure a steady mupirocin supply?
Providers should establish relationships with multiple qualified suppliers, participate in inventory planning, and monitor supply chain risks proactively.
References
[1] GlaxoSmithKline. Bactroban Official Website. Accessed 2023.
More… ↓
